Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Targets & Mechanisms

Regeneron's new take on bispecifics: activating complement

Why Regeneron built a bispecific platform that harnesses the complement system

Allison Johnson, Senior Writer
September 19, 2019 6:57 PM UTC

Regeneron's new bispecific antibodies for the first time tap the complement system -- going beyond the immune cells traditionally targeted, and expanding the modality into new patient populations and indications.

With proof of concept studies against bacteria as well as cancer, the data advance the possibility that bispecifics could add to the sorely needed armamentarium of agents to overcome antimicrobial resistance...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Regeneron Pharmaceuticals Inc.